Introduction
A changing pattern of values, termed a delta value, is an essential component of the diagnosis of acute myocardial infarction (AMI) both with CK-MB and even more so with cardiac troponins (cTn). 1 Given the low index of individuality in studies of biological variation, 2 as well as clinical experience, it is clear that a changing pattern of values (A delta) will be important. [3] [4] [5] [6] [7] As cTn assays become more sensitive, such a strategy will become more essential as the frequency of chronic elevations will increase. 8 Studies defining the delta that might distinguish AMI from other diseases, including some that may also cause rising patterns (e.g. pulmonary embolism and heart failure) often have used samples collected for other reasons making some analyses less than ideal. Nonetheless, their publication has led to the idea that this answer is known. [3] [4] [5] [6] [7] The present manuscript was developed to explore the gaps in information about this important issue and to propose criteria for studies to define these changes more definitively.
Gaps (Table 1)
There are multiple publications exploring delta changes [3] [4] [5] [6] [7] and studies that have measured conjoint analytical and biological variation. 2 All such studies indicate that values of 30%-85% are needed to be sure that a given change is due to pathobiology alone. 2 The clinical studies often contain heterogeneous populations of patients but they all suggest a tension between sensitivity and specificity as one might anticipate given distinctions are made often in populations that include patients with changing patterns due to confounding disease states such those with atrial fibrillation which manifest elevated cTn values. 9 These sorts of issues have not been culled out rigorously in the accumulating literature.
In addition, many studies have included patients with STEMI or with overt myocardial infarctions. These individuals have marked increases in cTn over time and will, if they are a significant part of the population exaggerate the delta calculation. Similarly, some studies have included patients who have no delta at all. 9,10 Some of these patients may be late presenters making the In search for the Holy Grail: Suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association likelihood of a delta change over a short period smaller than expected as they may be on the flat part of the time concentration curve. 10 One could argue that such patients could still have myocardial infarction based on other metrics. Others might argue to exclude such patients, as they 'cannot have unstable coronary artery disease without a changing pattern of values over a short period of time'. 11 Including these patients will diminish the delta calculation, perhaps markedly if they are a major part of the population. In addition, studies have often utilized non-high sensitivity cTn assays with variable cut off values as a gold standard. 12 This approach will also include patients with larger myocardial infarctions who will have larger increases in a delta and by excluding the additional patients detected a high sensitivity cTn assay increase the delta calculation (see Figure 1 ).
In many studies, samples were collected to evaluate diagnostic sensitivity and specificity in patients presenting with possible myocardial infarction. Many of these cohorts understandably do not have late samples in all patients. This has the potential to change the delta since the late diagnosis of myocardial infarction is likely to include subtler cases 8 not detected with the existing assays that need to be included in comprehensive evaluations of a delta strategy. In addition, there often is not subsetting of patients by the time of symptom onset. This is difficult clinically. Some patients have difficulties in defining the onset of symptoms accurately and the onset symptoms might not necessarily be the onset of myocardial infarction. Many patients have repeated episodes of chest pain before admission to hospital. One might have very different deltas early after the onset of symptoms but different deltas late and there are other subgroups that could be differential as well. There also is concern that women, because they have more endothelial dysfunction and less fixed coronary disease, may have different deltas. 13 These issues have not been systematically probed.
No attempt has been made as yet to distinguish delta between Type 1 and Type 2 AMI. Since these entities may require different therapies, this issue could be important.
Despite these lacks; strategies predicated on a delta pattern are being advocated and implemented. 14 To address some of the remaining issues, we would suggest that adherence to specific criteria be held in abeyance when studying these critical issues. This manuscript will not attempt to define every metric but the overall strategy is one that the members of the group endorse as providing a robust template for collecting information about this important issue. It is also understood that all institutions may not be able to follow all of the suggestions included, but unless we understand the optimal, it will be hard to evaluate how important studies which deviate from the more ideal might be. hours or less should be indicated. Given the difficulties of ascertaining the onset of symptoms reliably, prospective criteria should be developed and adhered to. Three groups would likely emerge; one where there is high confidence of an onset within 6 hours, a second where there is high confidence of an onset between 6 and 24 hours, and a group where the onset is ambiguous. 5. Studies should, however, ideally enroll 'all comers', defining a high group with a high pretest likelihood for AMI to compare to those with a lower pre-test likelihood would be informative. One could even argue that different criteria may be needed to optimally separate patients in each of these groups. 6. Patients should be ruled out or ruled in with the high-sensitivity cTn assay that is being evaluated. It needs to be assumed that each cTn assay will be unique. Extrapolation of results from one assay to another is not appropriate until such an approach has been validated. Absolute changes may be more difficult to extrapolate than relative ones. 7. Sampling should be done in all patients frequently as determined prospectively. Samples at zero time, 3 and 6 hours would be optimal but earlier samples might also be evaluated. In patients with elevated levels and no rise over 3-6 hours, it would be optimal to have an additional sample 1-3 days later. Samples should be frozen and stored for subsequent analyses with other assays. 8. It would be ideal to have multiple high-sensitivity cTn assays measured in the same data set but this of course will depend on the availability of these assays and the sites involved. The diagnosis should be carefully adjudicated centrally according to prospectively defined criteria that are detailed in the publication. 9. Clinical judgment is always appropriate in the management of patients and will no doubt be useful in classifying the diagnoses in these patients. However, it is difficult to codify clinical judgment. Thus, whenever possible, more objective information should be obtained. Accordingly, ideally, patients should all have angiographic evaluation. It would be helpful, since there is overlap between the angiographic criteria seen in patients with stable coronary disease and those with unstable coronary disease, 15 that IVUS and/or optical coherence tomography be done whenever there is question about whether or not the potential culprit lesion is an acute lesion. Those who are deemed not to have an acute coronary syndrome could also be evaluated by coronary CTA. The investment in coronary CTA to make sure that these individuals do not include patients with coronary disease that was missed would be important, especially in those with a rising pattern of cardiac cTn values. Some sites might prefer to use imaging modalities to detect ischemia; MRI may be particularly useful. 10. Patients should be subset by gender, using genderderived 99th percentile values and ethnicity. 11. Both absolute and relative deltas should be calculated, and the 95th confidence intervals given. Calculations should be done for values below or at the 99th% URL and in patients with baseline elevations since some studies have argued that these approaches are more similar near the 99th percentile than when the initial values are elevated. 12. Subsetting by whether the baseline cTn value is elevated may be subsumed based on timing but if not, it should be probed. 13. Potential differences between Type 1 and Type 2 AMI should be evaluated. 14. ROC analysis should be utilized to find the optimal criteria for the combination of rule out and rule in. It is unlikely that any delta will be perfect. It may also be that the optimal delta values will be different for rule in and rule out. In addition, given the purpose of looking for change is to improve specificity, a graphic description of the relationship between sensitivity and specificity should be provided.
Some criteria for proposed studies
These studies would permit accurate determination of the optimal deltas and provide robust information for clinicians. It is unclear at present how large this study might need to be but if entertained, power calculations would be necessary to be sure the answers that are necessary are obtained.
